Tetra Bio-Pharma Inc. (
TSX: V.TBP,
OTCQB: GRPOF,
Forum) said Thursday a clinical study on cannabis oil capsules for patients suffering from chronic pain should be completed by the fall of 2018.
In a status report on its encapsulated cannabis oils (PPP005) clinical trials, the company said these cannabis products are ready to commercialize in the retail market post legalization.
The company said the authorization from the Office of Controlled Substances marks the initiation of the treatment phase of the Phase 2 clinical trial that will be used to support Product Licence Applications post legalization.
More information can be found
here.
Tetra Bio-Pharma recently said it has received Health Canada Phase 3 Clinical Trial Approval for its PPP001 Smokable Dried Cannabis Prescription Drug.
Coinciding with World Cancer Day 2018, Tetra is now ready to initiate Phase 3 clinical train for PPP001 in terminal cancer patients.
Tetra is a world leader in the drug development field of cannabis-based medications and is paving the road to become the first company to commercialize a dried marijuana product as a drug in North America.
The Ontario-based company was in the news recently when it and and
Aphria Inc. (
TSX: V.APH,
OTCQB: APHQF,
Forum) announced plans for
the joint distribution of dried medical cannabis in the maritime provinces and Quebec. Full Disclosure: Tetra Bio-Pharma Inc. is a paid client of Stockhouse Publishing.